POST-DISCHARGE MORTALITY AND READMISSION IN HEART FAILURE PATIENTS WITH PRESERVED, BORDERLINE, AND REDUCED LEFT VENTRICULAR EJECTION FRACTION (original) (raw)
Related papers
Pakistan Journal of Health Sciences, 2022
Heart failure is a well-known clinical condition and the number of hospital admissions with decompensated heart failure is increasing, mainly due to the increasing age of the population [1, 2]. It is estimated to affect 26 million people worldwide, with over one million admissions yearly in both the Europe and United States [3, 4]. In the US, the annual incidence of newly diagnosed heart failure is 670,000 cases per year. It has been reported that between one-third and one-half of HF patients maintain their ejection fraction, and these patients, especially in older age groups, may replace HF patients with reduced ejection fractions [5]. These patients tend to be older and have a different risk factor pro le compared to patients with low ejection
Outcomes in heart failure patients with preserved ejection fraction
Journal of the American College of Cardiology, 2003
We evaluated the six-month clinical trajectory of patients hospitalized for heart failure (HF) with preserved ejection fraction (EF), as the natural history of this condition has not been well established. We compared mortality, hospital readmission, and changes in functional status in patients with preserved versus depressed EF. BACKGROUND Although the poor prognosis of HF with depressed EF has been extensively documented, there are only limited and conflicting data concerning clinical outcomes for patients with preserved EF.
2020
Heart failure with reduced ejection fraction (HFrEF) is a progressive clinical syndrome defined by changes in the myocardial structure, which lead to predominant systolic myocardial function impairment, with a left ventricle ejection of fraction ≤40%. The rehospitalization burden in HFrEF patients (pts) remains very high, with poor quality of life, increased mortality and large healthcare expenditures. In this research project, we investigated the risk factors for first and repeated hospitalization in pts with HFrEF. This retrospective study included 50 adult pts with a diagnosis of HFrEF and who were within the age range of 55 to 89 years old and of both sexes. Demographic and clinical data (HFrEF etiology, renal function parameters, complete blood count, markers of inflammation, electrocardiogram, troponin I, NTproBNP, echocardiographic parameters and comorbidities data) were collected from the pts’ medical histories. Statistical analysis was performed via Fischer’s exact test, th...
Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction
Journal of Osteopathic Medicine, 2020
Context Cases of heart failure with preserved ejection fraction (HFpEF) exacerbations continue to affect patients' quality of life and cause significant financial burden on our healthcare system. Objective To identify risk factors for readmission in patients discharged with a diagnosis of HFpEF. Methods Electronic health records of patients over 18 years of age with a primary diagnosis of HFpEF treated between August 1, 2017 and March 1, 2018 in a community hospital were retrospectively reviewed. The study population included patients with HFpEF greater than 40% who were screened but did not qualify for the ongoing CONNECT- HF trial being conducted by Duke Clinical Research. To be included, subjects had to fall into 1 of 2 classifications (NYHA Class II-IV or ACC/AHA Stage B-D) and have a life expectancy greater than 6 months. Patients were excluded if they had terminal illness other than HF, a prior heart transplant or were on a transplant list, a current or planned placement o...
Recovered heart failure with reduced ejection fraction and outcomes: a prospective study
European journal of heart failure, 2017
Significant recovery of left ventricular ejection fraction (LVEF) occurs in a proportion of patients with heart failure (HF) and reduced ejection fraction (HFrEF). We analysed outcomes, including mortality [all-cause, cardiovascular (CV), HF-related, and sudden death], and HF-related hospitalizations in this HF-recovered group. The primary endpoint was a composite of CV death or HF hospitalization. LVEF was assessed at baseline and at 1 year in 1057 consecutive HF patients. Patients were classified into three groups: (i) HF-recovered: LVEF <45% at baseline and ≥45% at 1 year (n = 233); (ii) HF with preserved EF (HFpEF): LVEF ≥45% throughout follow-up (n = 117); and (iii) HFrEF: LVEF <45% throughout follow-up (n = 707). Mean follow-up was 5.6 ± 3.1 years. HF-recovered patients differed from HFrEF and HFpEF groups in demographic and clinical characteristics. The mean LVEF increase was 21.1 ± 10 points in HF-recovered patients. Using the HF-recovered group as a reference, the ris...
European Heart Journal - Cardiovascular Imaging
Aims Newly introduced drugs for heart failure (HF) have been reported to improve the prognosis of HF with preserved ejection fraction (HFpEF) in the lower range of left ventricular ejection fraction (LVEF). We hypothesized that a higher LVEF is related to an unfavourable prognosis in patients with HFpEF. Methods and results We tested this hypothesis by analysing the data from a prospective multicentre cohort study in 255 patients admitted to the hospital due to decompensated HF (LVEF > 40% at discharge). The primary endpoint of this study was a composite outcome of all-cause death and readmission due to HF, and the secondary endpoint was readmission due to HF. LVEF and the mitral E/e′ ratio were measured using echocardiography. In multicovariate parametric survival time analysis, LVEF [hazard ratio (HR) = 1.046 per 1% increase, P = 0.001], concurrent atrial fibrillation (AF) (HR = 3.203, P < 0.001), and E/e′ (HR = 1.083 per 1.0 increase, P < 0.001) were significantly correl...
JACC: Heart Failure, 2015
The aim of this study was to investigate prognosis in patients with heart failure (HF) with preserved ejection fraction and the causes of hospitalization and post-hospitalization mortality. BACKGROUND Although hospitalizations in patients with HF with preserved ejection fraction are common, there are limited data from clinical trials on the causes of admission and the influence of hospitalizations on subsequent mortality risk. METHODS Patients (n ¼ 4,128) with New York Heart Association functional class II to IV HF and left ventricular ejection fractions >45% were enrolled in I-PRESERVE (Irbesartan in Heart Failure and Preserved Ejection Fraction). A blinded events committee adjudicated cardiovascular hospitalizations and all deaths using predefined and standardized definitions. The risk for death after HF, any-cause, or non-HF hospitalization was assessed using time-dependent Cox proportional hazard models. RESULTS A total of 2,278 patients had 5,863 hospitalizations during the 49 months of follow-up, of which 3,585 (61%) were recurrent hospitalizations. For any-cause hospitalizations, 26.5% of patients died during follow-up, with an incident mortality rate of 11.1 deaths per 100 patient-years (PYs) and an adjusted hazard ratio of 5.32 (95% confidence interval: 4.21 to 6.23). Overall, 53.6% of hospitalizations were classified as cardiovascular and 43.7% as noncardiovascular, with 2.7% not classifiable. HF was the largest single cause of initial (17.6%) and overall (21.1%) hospitalizations, although, after HF hospitalization, a substantially higher proportion of readmissions were due to primary HF causes (40%). HF hospitalization occurred in 685 patients, with 41% deaths during follow-up, an incident mortality rate of 19.3 deaths per 100 PYs. The adjusted hazard ratio was 2.93 (95% confidence interval: 2.40 to 3.57) relative to patients who were not hospitalized for HF and was greater in those with longer durations of hospitalization. There were 1,593 patients with only non-HF hospitalizations, 21% of whom died during follow-up, with an incident mortality rate of 8.7 deaths per 100 PYs and an adjusted hazard ratio of 4.25 (95% confidence interval: 3.27 to 5.32). The risk for death was highest in the first 30 days and declined over time for all hospitalization categories. Patients not hospitalized for HF or for any cause had observed incident mortality rates of 3.8 and 1.3 deaths per 100 PYs, respectively. CONCLUSIONS In I-PRESERVE, HFpEF patients hospitalized for any reason, and especially for HF, were at high risk for subsequent death, particularly early. The findings support the need for careful attention in the post-discharge time period including attention to comorbid conditions. Among those hospitalized for HF, the high mortality rate and increased proportion of readmissions due to HF (highest during the first 30 days), suggest that this group would be an appropriate target for investigation of new interventions.
Clinical Medicine And Health Research Journal, 2024
Introduction: Heart failure with moderately impaired ejection fraction (HFmEF) has garnered increasing attention in recent years. However, understanding this new phenotype, particularly concerning morbidity and mortality, remains limited. Materials and Methods: A prospective, observational, and single-center study spanning 26 months was conducted on 204 patients with HFmEF selected from 447 patients with chronic heart failure (CHF) categorized based on their left ventricular ejection fraction (LVEF): HF with reduced ejection fraction (HFrEF) if LVEF ≤ 40% (n = 173) and HF with preserved ejection fraction (HFpEF) if LVEF ≥ 50% (n = 70). This study included a detailed evaluation of factors precipitating cardiovascular (CV) death and rehospitalizations in patients with HFmEF. Results: After a mean follow-up of 431 days in the HFmEF patient group, our results indicated that CV mortality at six months was 2.5%, and at one year, it was 5.9%. Prognostic factors for survival included chronic kidney disease, blood glucose level > 1.4g/l, presence of moderate to severe secondary mitral insufficiency, sphericity index < 1.7, elevated pulmonary vascular resistance, and resistance to diuretic treatment. HF rehospitalization rates at 6 and 12 months were 2.5% and 8.3%, respectively. Predictive factors for HF rehospitalizations included diabetes, hemoglobin level < 13g/dl, left atrial volume > 34 ml/m 3-, mitral S-wave < 0.05cm/s, non-improvement of global longitudinal strain, and resistance to diuretic treatment. Conclusion: This category of HF remains underrecognized and neglected by practitioners, and its prognosis is formidable, especially in the presence of adverse prognostic factors.
The American Journal of Medicine, 2019
Background: A prior hospitalization due to heart failure is associated with poor outcomes in ambulatory patients with heart failure. Less is known about this association in hospitalized patients with heart failure and whether it varies by ejection fraction. Methods: Of the 25,345 hospitalized patients in Medicare-linked OPTIMIZE-HF registry, 22,491 had known heart failure, of whom 7648 and 9558 had heart failure with preserved (≥50%) and reduced (≤40%) ejection fraction (HFpEF and HFrEF), respectively. Overall, 927 and 1862 patients with HFpEF and HFrEF had heart failure hospitalizations during six months before the index hospitalization, respectively. Using propensity scores for prior heart failure hospitalization, we assembled two matched cohorts of 924 pairs and 1844 pairs of patients with HFpEF and HFrEF, respectively, each balanced for 58 baseline characteristics. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes during six years of follow-up. Results: Among 1848 matched patients with HFpEF, HRs (95% CIs) for all-cause mortality, allcause readmission and heart failure readmission were 1.35 (1.21-1.50; p<0.001), 1.34 (1.21-1.47; p<0.001) and 1.90 (1.67-2.16; p<0.001), respectively. Respective HRs (95% CIs) in 3688 matched patients with HFrEF were 1.17 (1.09-1.26; p<0.001), 1.32 (1.23-1.41; p<0.001), and 1.48 (1.37-1.61; p<0.001). Conclusions: Among hospitalized patients with heart failure, a prior heart failure hospitalization is associated with higher risks of mortality and readmission in both HFpEF and HFrEF. The relative risks of death and heart failure readmission appear to be higher in HFpEF than in HFrEF.